APGE

Apogee Therapeutics, Inc.

Fundamental data last updated:September 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

 


Analyze APGE on TradingView

VALUATION

P/E

-19.74

Market Cap ($M USD)

$4.82B

Forward P/E

-77.20

PEG

-1.04

PRICE TO SALES

0.00

PRICE TO BOOK

4.32

EV / EBITDA

-14.71

5-Year Average P/E

Free Cash Flow Yield

-4.89%

DCF Value

$2.00

Graham Number

N/A

Price to FCF

-20.47

EV to FCF

-18.58

Earnings Yield

-5.07%

FCF Yield

-4.89%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.94

Next Year EPS Growth Estimate

-$1.01

Next Year Revenue Growth Estimate

$824.44M

Return on Equity (ROE)

-32.64%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.01

Piotroski F-Score

2

Altman Z-Score

76.35

Return on Invested Capital (ROIC)

-24.21%

Current Ratio

32.59

Quick Ratio

32.59

Net Debt to EBITDA

1.49

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-3.38

REVENUE PER SHARE

$0.00

Analyze APGE on TradingView

Gainseekers Quantitative Analysis

Summary

APGE’s valuation is a paradox wrapped in a biotech enigma. Despite a staggering Altman Z-score of 91.76, indicating financial safety, the market seems to have mispriced it relative to its DCF value, which is a mere fraction of its snapshot price. The Forward P/E and negative Earnings Yield suggest a company priced for growth that hasn’t materialized, while the negative ROIC and EPS paint a picture of operational inefficiency. The market cap is hefty, yet the fundamentals scream caution, with a Price/Book ratio that hints at overvaluation.

AI Exposure / Tech Reliance

In the rapidly evolving biotech sector, Apogee Therapeutics stands poised to leverage AI for drug discovery and personalized medicine. This adaptability is crucial as the industry shifts towards more data-driven approaches. Their positioning in biotechnology suggests potential resilience in integrating cutting-edge technologies.

The Bull Case

For the optimistic investor, APGE offers a compelling narrative of potential growth. The company's negligible debt and a Current Ratio of 26.57 highlight a fortress-like balance sheet, providing a cushion for future investments. Despite a low Piotroski F-Score, the consensus rating of "Buy" and a mean target price significantly above the snapshot price suggest institutional confidence. The potential for explosive sales growth next year could translate into substantial returns if management capitalizes on its capital efficiency.

The Bear Case

However, the bear case is hard to ignore. The negative Price to FCF and Earnings Yield indicate a company struggling to generate cash flow, while the Price/Book ratio suggests overvaluation. With an EPS of -$4.22 and a Forward P/E of -81.85, the financials reveal a company burning through cash without immediate profitability. The stock's proximity to its 52-week high raises concerns about technical overextension, making it a risky bet for those wary of speculative plays.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$109.73

Institutional Ownership %

1-Year Beta

0.69

Insider Buying % (6 Mo)

Distance to 52-Week High

22.48%

Distance to 52-Week Low

55.87%

EARNINGS SURPRISE %

5.36%

50-DAY SMA

$82.55

200-DAY SMA

$65.76

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.